URGNbenzinga

UroGen Announces Outcome Of ODAC For UGN-102 For Treatment Of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Summary

No summary available.

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on May 21, 2025 by benzinga

    UroGen Announces Outcome Of ODAC For UGN-102 For Treatment Of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer | URGN Stock News | Candlesense